230 related articles for article (PubMed ID: 31925805)
1. Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities.
Goeppert B; Folseraas T; Roessler S; Kloor M; Volckmar AL; Endris V; Buchhalter I; Stenzinger A; Grzyb K; Grimsrud MM; Gornicka B; von Seth E; Reynolds GM; Franke A; Gotthardt DN; Mehrabi A; Cheung A; Verheij J; Arola J; Mäkisalo H; Eide TJ; Weidemann S; Cheville JC; Mazza G; Hirschfield GM; Ponsioen CY; Bergquist A; Milkiewicz P; Lazaridis KN; Schramm C; Manns MP; Färkkilä M; Vogel A; ; Boberg KM; Schirmacher P; Karlsen TH
Hepatology; 2020 Oct; 72(4):1253-1266. PubMed ID: 31925805
[TBL] [Abstract][Full Text] [Related]
2. Mutational spectrum and precision oncology for biliary tract carcinoma.
Lin J; Cao Y; Yang X; Li G; Shi Y; Wang D; Long J; Song Y; Mao J; Xie F; Bai Y; Zhang L; Yang X; Wan X; Wang A; Guan M; Zhao L; Hu K; Pan J; Huo L; Lu X; Mao Y; Sang X; Zhang H; Wang K; Wang X; Zhao H
Theranostics; 2021; 11(10):4585-4598. PubMed ID: 33754015
[No Abstract] [Full Text] [Related]
3. Primary Sclerosing Cholangitis-Associated Cholangiocarcinoma Demonstrates High Intertumor and Intratumor Heterogeneity.
Kamp EJCA; Peppelenbosch MP; Doukas M; Verheij J; Ponsioen CY; van Marion R; Bruno MJ; Groot Koerkamp B; Dinjens WNM; de Vries AC
Clin Transl Gastroenterol; 2021 Oct; 12(10):e00410. PubMed ID: 34608877
[TBL] [Abstract][Full Text] [Related]
4. Genetic alterations during the neoplastic cascade towards cholangiocarcinoma in primary sclerosing cholangitis.
Kamp EJ; Dinjens WN; Doukas M; van Marion R; Verheij J; Ponsioen CY; Bruno MJ; Groot Koerkamp B; Trivedi PJ; Peppelenbosch MP; de Vries AC
J Pathol; 2022 Nov; 258(3):227-235. PubMed ID: 35897137
[TBL] [Abstract][Full Text] [Related]
5. Biliary dysplasia, cell proliferation and nuclear DNA-fragmentation in primary sclerosing cholangitis with and without cholangiocarcinoma.
Bergquist A; Glaumann H; Stål P; Wang GS; Broomé U
J Intern Med; 2001 Jan; 249(1):69-75. PubMed ID: 11168786
[TBL] [Abstract][Full Text] [Related]
6. p16INK4a promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC-associated cholangiocarcinoma.
Taniai M; Higuchi H; Burgart LJ; Gores GJ
Gastroenterology; 2002 Oct; 123(4):1090-8. PubMed ID: 12360471
[TBL] [Abstract][Full Text] [Related]
7. Cholangiocarcinoma in primary sclerosing cholangitis: K-ras mutations and Tp53 dysfunction are implicated in the neoplastic development.
Boberg KM; Schrumpf E; Bergquist A; Broomé U; Pares A; Remotti H; Schjölberg A; Spurkland A; Clausen OP
J Hepatol; 2000 Mar; 32(3):374-80. PubMed ID: 10735605
[TBL] [Abstract][Full Text] [Related]
8. Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures.
Mody K; Jain P; El-Refai SM; Azad NS; Zabransky DJ; Baretti M; Shroff RT; Kelley RK; El-Khouiery AB; Hockenberry AJ; Lau D; Lesinski GB; Yarchoan M
JCO Precis Oncol; 2022 Jun; 6():e2100510. PubMed ID: 35675577
[TBL] [Abstract][Full Text] [Related]
9. p53 overexpression and K-ras gene mutations in primary sclerosing cholangitis-associated biliary tract cancer.
Ahrendt SA; Rashid A; Chow JT; Eisenberger CF; Pitt HA; Sidransky D
J Hepatobiliary Pancreat Surg; 2000; 7(4):426-31. PubMed ID: 11180865
[TBL] [Abstract][Full Text] [Related]
10. Intraductal papillary neoplasms of the bile duct: stepwise progression to carcinoma involves common molecular pathways.
Schlitter AM; Born D; Bettstetter M; Specht K; Kim-Fuchs C; Riener MO; Jeliazkova P; Sipos B; Siveke JT; Terris B; Zen Y; Schuster T; Höfler H; Perren A; Klöppel G; Esposito I
Mod Pathol; 2014 Jan; 27(1):73-86. PubMed ID: 23828315
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic KRAS-expressing organoids with biliary epithelial stem cell properties give rise to biliary tract cancer in mice.
Kasuga A; Semba T; Sato R; Nobusue H; Sugihara E; Takaishi H; Kanai T; Saya H; Arima Y
Cancer Sci; 2021 May; 112(5):1822-1838. PubMed ID: 33068050
[TBL] [Abstract][Full Text] [Related]
12. Chromosome 9p21 loss and p16 inactivation in primary sclerosing cholangitis-associated cholangiocarcinoma.
Ahrendt SA; Eisenberger CF; Yip L; Rashid A; Chow JT; Pitt HA; Sidransky D
J Surg Res; 1999 Jun; 84(1):88-93. PubMed ID: 10334895
[TBL] [Abstract][Full Text] [Related]
13. K-ras mutations in the bile of patients with primary sclerosing cholangitis.
Kubicka S; Kühnel F; Flemming P; Hain B; Kezmic N; Rudolph KL; Manns M; Meier PN
Gut; 2001 Mar; 48(3):403-8. PubMed ID: 11171833
[TBL] [Abstract][Full Text] [Related]
14. Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.
Boerner T; Drill E; Pak LM; Nguyen B; Sigel CS; Doussot A; Shin P; Goldman DA; Gonen M; Allen PJ; Balachandran VP; Cercek A; Harding J; Solit DB; Schultz N; Kundra R; Walch H; D'Angelica MI; DeMatteo RP; Drebin J; Kemeny NE; Kingham TP; Simpson AL; Hechtman JF; Vakiani E; Lowery MA; Ijzermans JNM; Buettner S; Koerkamp BG; Doukas M; Chandwani R; Jarnagin WR
Hepatology; 2021 Sep; 74(3):1429-1444. PubMed ID: 33765338
[TBL] [Abstract][Full Text] [Related]
15. Anatomical, histomorphological and molecular classification of cholangiocarcinoma.
Kendall T; Verheij J; Gaudio E; Evert M; Guido M; Goeppert B; Carpino G
Liver Int; 2019 May; 39 Suppl 1():7-18. PubMed ID: 30882996
[TBL] [Abstract][Full Text] [Related]
16. Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma.
Lewis JT; Talwalkar JA; Rosen CB; Smyrk TC; Abraham SC
Am J Surg Pathol; 2010 Jan; 34(1):27-34. PubMed ID: 19898228
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker.
Chae H; Kim D; Yoo C; Kim KP; Jeong JH; Chang HM; Lee SS; Park DH; Song TJ; Hwang S; Kim KH; Song GW; Ahn CS; Lee JH; Hwang DW; Kim SC; Jang SJ; Hong SM; Kim TW; Ryoo BY
Eur J Cancer; 2019 Oct; 120():31-39. PubMed ID: 31476489
[TBL] [Abstract][Full Text] [Related]
18. Next-generation sequencing mutation analysis on biliary brush cytology for differentiation of benign and malignant strictures in primary sclerosing cholangitis.
Kamp EJCA; Dinjens WNM; van Velthuysen MF; de Jonge PJF; Bruno MJ; Peppelenbosch MP; de Vries AC
Gastrointest Endosc; 2023 Mar; 97(3):456-465.e6. PubMed ID: 36252869
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention.
Lowery MA; Ptashkin R; Jordan E; Berger MF; Zehir A; Capanu M; Kemeny NE; O'Reilly EM; El-Dika I; Jarnagin WR; Harding JJ; D'Angelica MI; Cercek A; Hechtman JF; Solit DB; Schultz N; Hyman DM; Klimstra DS; Saltz LB; Abou-Alfa GK
Clin Cancer Res; 2018 Sep; 24(17):4154-4161. PubMed ID: 29848569
[No Abstract] [Full Text] [Related]
20. Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers.
Tang TY; Nichetti F; Kaplan B; Lonardi S; Pietrantonio F; Salvatore L; Vivaldi C; Rimassa L; de Braud F; Rizzato MD; Pavlick D; Chu R; Danner De Armas A; Sharaf R; Sokol E; Rodon Ahnert J; Ross JS; Javle M; Niger M
Clin Cancer Res; 2023 Dec; 29(23):4853-4862. PubMed ID: 37773629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
